Medpace Holdings, Inc.
Nasdaq: MEDP·Cincinnati, Ohio·CIK 0001668397
- Price
- $648.20
- Base IV
- $302.53
Valuation snapshot
At $648.20, the price is above even our bull case of $435.32.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $302.53
- 47% of the price · range $190.68–$435.32
- Price vs base case
- 114% above
- $648.20 against $302.53
- Base case · our researched forecast, 2026-10-31See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 4.3% since this valuation was struck on 2026-10-31, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $190.68 to bull $435.32. Values per share.
Price against each value
- Bear case
- $190.68
- Price 240% above
- No growth
- …
- —
- Base case
- $302.53
- Price 114% above
What does Medpace Holdings do?
Medpace provides outsourced clinical development services to biotechnology and pharmaceutical companies to manage and execute Phase I-IV clinical trials for new drugs and medical devices.
It brought in $2.8B of sales in the 12 months to Sep 2026.
- Industry
- Healthcare
- Based in
- Cincinnati, Ohio
- Trades on
- Nasdaq as MEDP
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 18¢ was left as profit after every cost, interest and tax. The biggest cost is everything else it takes to operate, 72¢ of every dollar.
- Sales, marketing and admin7¢
- Everything else it takes to operate72¢
- Tax4¢
- Left as profit18¢
- Interest and other income came back in+1¢
Who pays Medpace Holdings, and for what?
Medpace is a clinical contract research organization that manages clinical trials for drug and medical device companies. It provides full-service clinical development from Phase I through Phase IV, including trial management, medical monitoring, regulatory affairs, and central laboratory testing. It makes money by charging fixed fees or unit-of-service fees as contracted trial services are performed.
The company is paid by biotechnology, pharmaceutical, and medical device companies, with a primary focus on small and mid-sized biopharmaceutical firms.
Clinical development services
100%Full-service outsourced Phase I to IV clinical development services, central laboratory, bioanalytical laboratory, and clinical pharmacology services.
Where its work physically happens, beyond headquarters:
- Medpace Leuven Laboratory and Logistics Campus — Leuven, Belgium. Medpace owns these buildings, which house laboratory, office and logistics operations and make Leuven its European central laboratory site and only disclosed owned property outside Cincinnati, supporting sample processing for European trials.
- Medpace Central Laboratory Shanghai — Shanghai, China. One of only four central laboratory locations named in the 10-K, it gives Medpace in-house lab capacity for clinical trials in China.
- Medpace Central Laboratory Singapore — Singapore, Singapore. One of only four central laboratory locations named in the 10-K, it gives Medpace in-house lab capacity to support clinical trials across the Asia-Pacific region.
How is the business doing?
Sales grew from $925.9M in 2020 to $2.5B in 2025, about 22% a year.
Running the business leaves about 21¢ of each sales dollar as operating profit, up from 18¢ in 2020.
After paying for its upkeep and new investment, it had $667.6M of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
The company exists to speed up the worldwide clinical testing and approval of safe and effective medical treatments.
“To accelerate the global development of safe and effective medical therapeutics.”
What management says it is working on now:
Organic market share expansion
Growing its share of the Phase I-IV outsourced clinical development market across major therapeutic areas, especially Oncology, Metabolic, and Central Nervous System.
Medpace Holdings, Inc. 2025 Form 10-KCore customer relationship depth
Deepening relationships and winning new full-service accounts within small and mid-sized biopharmaceutical companies through integrated medical and operational expertise.
Medpace Holdings, Inc. 2025 Form 10-KOperating margin discipline
Maintaining strong operating margins by executing trials through a centralized operating model and tightly controlling costs.
Medpace Holdings, Inc. 2025 Form 10-KTalent retention and development
Attracting, training, and retaining scientific, medical, and operational staff to support growing trial volume and preserve service quality.
Medpace Holdings, Inc. 2025 Form 10-KCapital return through share buybacks
Deploying operating cash flow into share repurchases, utilizing authorized buyback programs while preserving sufficient operational liquidity.
Medpace Holdings, Inc. 2025 Form 10-K
- Full-year revenue, Full year 2026
- $2.835 billion to $2.855 billion
- Medpace Holdings, Inc. Reports Third Quarter 2026 Results
- GAAP net income, Full year 2026
- $514.0 million to $524.0 million
- Medpace Holdings, Inc. Reports Third Quarter 2026 Results
- EBITDA, Full year 2026
- $638.0 million to $652.0 million
- Medpace Holdings, Inc. Reports Third Quarter 2026 Results
- Diluted earnings per share, Full year 2026
- $17.97 to $18.32
- Medpace Holdings, Inc. Reports Third Quarter 2026 Results
- Backlog conversion to net revenue in 2026, Full year 2026
- $1,890.0 million to $1,910.0 million
- Medpace Holdings, Inc. 2025 Form 10-K
What's changing right now?
Growth is slowing. In Q3 2026 it sold 9% more than a year earlier. The year before, quarters averaged 25%.
Its operating margin is wider than a year ago: 23¢ per sales dollar, against 21¢.
Since Oct 2026 the share price has fallen 4%, from $677.56 to $648.20.
Coming up
February 2027
Q4 and full-year 2026 earnings release and initial 2027 guidance
Medpace will report its final fourth-quarter and full-year 2026 financial results and intends to issue its initial formal financial guidance for full-year 2027.
Medpace Holdings Q3 2026 Earnings Call CommentaryMay 2027
2027 Annual Meeting of Stockholders
Medpace convenes its annual meeting of stockholders to conduct regular corporate governance votes and review company performance.
Medpace Holdings Investor Relations Events
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Contract cancellations and delays
Customers can typically cancel trials without cause on 30 days' notice if clinical trials fail, drug priorities change, or funding runs out, reducing expected revenue.
From the company's own filingsWould hit how fast sales growMedpace Holdings, Inc. 2025 Form 10-K
Exposure to small and mid-sized biopharma funding
Small and mid-sized biopharma firms accounted for 95% of 2025 net revenue. These clients depend on capital markets and may pause or cancel trials if funding dries up.
From the company's own filingsWould hit how fast sales growMedpace Holdings, Inc. 2025 Form 10-K
Fixed-fee contract overruns and change orders
Most trial contracts are fixed-fee. If Medpace underestimates expenses or fails to obtain client approval for change orders, the company must absorb the extra costs.
From the company's own filingsWould hit how much of each sale it keepsMedpace Holdings, Inc. 2025 Form 10-K
Customer and therapeutic concentration
The top 10 customers generated 35.1% of 2025 net revenue. Losing any large client or facing class-wide drug failures in key areas like oncology could harm results.
From the company's own filingsWould hit how fast sales growMedpace Holdings, Inc. 2025 Form 10-K
Failure to recruit investigators and patients
Clinical studies require enrolling qualified physicians and patients. Inability to recruit enough participants on schedule can delay trials, raise costs, or cause contract losses.
From the company's own filingsWould hit how much of each sale it keepsMedpace Holdings, Inc. 2025 Form 10-K
Complex international operations and regulatory compliance
Operating trials across 46 countries exposes the business to strict Good Clinical Practice rules, cross-border data transfer laws, currency swings, and local political risks.
From the company's own filingsWould hit the tax it paysMedpace Holdings, Inc. 2025 Form 10-K
Quarterly year-over-year revenue growth moderated from 0.320 in Q4 2025 to 0.085 in Q3 2026, creating tough baseline comparisons.
From our researchWould hit how fast sales growMedpace Quarterly Earnings History
Quarter-to-quarter variability occurs due to reimbursable study pass-through costs and clinician bonus timing.
From our researchWould hit how much of each sale it keepsMedpace Q3 2026 Earnings Call Transcript
Is it a good business?
From 2017 to 2019 it earned between 8% and 18% on the capital invested in it, a median of 13%. Its cost of capital in the latest valuation is 9.6%; returns were above it in 2 of the 3 years.
From 2017 to 2025 it earned between 8% and 98% on its shareholders' equity, a median of 19%.
Over 9 years its operating margin ranged from 14¢ to 21¢ per sales dollar, a median of 18¢.
It bought back shares: the count fell 1.5% in a year, so each remaining share owns a slightly bigger slice.
What might it be worth?
Net debt is excluded: The last balance sheet with both cash and debt is too old for this valuation. The per-share value may change when resolved. Last published debt: $0 as of 2019-12-31.
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $648.20. Our put its value between $190.68 and $435.32, with $302.53 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $190.68
This scenario assumes that after sales expansion slowed to under nine percent in late 2026, tighter funding for early-stage biotechnology clients leads to reduced clinical trial activity and lower ongoing profits over the next five years.
Base case, $302.53
This scenario assumes that the company maintains healthy expansion around ten percent before gradually settling into steady single-digit gains, supported by over three billion dollars in committed customer contracts and stable operational profitability.
Bull case, $435.32
This scenario assumes that renewed biotechnology funding accelerates demand for clinical drug trials, allowing the company to sustain double-digit sales growth and return profit rates toward its recent peak levels.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 114%
For Medpace Holdings to be worth today's $648.20, sales would need to grow about 28.2% a year. We assume 8.5%. Over the last 5 years, sales grew 21.0% a year.
Or, if sales grow 8.5% as we assume, the price works with a profit margin of 46.1% (we assume 21.5%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 28.2% a year?
Try your own numbersWe're moderately sure of this range: it scores 71 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $302.53 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average8.5%
- Operating margin21.5%
- Long-term growth rate3.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$302.53 -53.3%


